treatment experience of thymoma & thymic carcinoma in teritiary cancer institute in india

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Thymoma and Thymic Cancer
Presenter VENKATESH Tirumala
Citation Annals of Oncology (2018) 29 (suppl_9): ix143-ix149. 10.1093/annonc/mdy446
Authors V. Tirumala, M.C. Suresh Babu, K. Govind Babu, D. Lokanatha, L.A. Jacob, K..N. Lokesh, A.H. Rudresha, L.K. Rajeev, S.C. Saldanha, G.V. Giri
  • Medical Oncology, Kidwai Cancer Institute, 560029 - Bangalore/IN

Abstract

Background

Thymic neoplasms are rare in incidence and relatively slow growing with late presentation. Thymoma are considered as potentially malignant and thymic carcinoma are malignant. Because of rarity and under reporting in India, there is an unmet need for treatments and response in our population.

Methods

This is a retrospective analytical study of patients diagnosed with thymoma and thymic carcinoma from June 2014 to June 2017 from a regional cancer centre in India. Data were recorded for epidemiological, clinical, histopathological, staging and treatment and outcome from patient files after taking consent.

Results

A total of 24 total patients were diagnosed and taken for treatment at our institute. The incidence of thymoma and thymic carcinoma appears to be relatively similar (1.4:1). Most of the patients presented in Masaoka Stage III and IV constituting 50% and 42%, respectively. Predominant WHO histological types were B3 and C. Most of the patients received chemotherapy either in neoadjuvant setting or palliative setting. Stage III patients with unresectabe tumors received NACT followed by surgery and RT. Stage IV patients received chemotherapy. The regimens used were cisplatin, doxorubicin, cyclophosphamide (CAP) and cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC) in both the NACT and palliative setting. Stage III patients had 2 yr PFS and 2 yr OS of 75% and 82.5% with a median OS of 30 months. For the patients with stage IV most of the patients had a durable response, with 2 yr PFS and OS of 40% and 60%, respectively. Responses are more durable with ADOC than with other regimens.

Conclusions

Thymoma and thymic carcinoma are rare tumours with low incidence but these tumours are highly responsive to chemotherapy with considerable PFS and OS. Patients treated with the ADOC regimen responded well with durable response.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Kidawi Cancer Institute.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.